Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | CBX7 | O95931 | 2/20 | 0.44 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.44 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.44 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10854210 | 0.88 | ATM (0.52) | ALDH1A1MAPTUSP30PTGER3CBX7 | |
| SCHEMBL3217163 | 0.83 | LMNA (0.54) | ALDH1A1MAPTUSP30PTGER3PDE3B | |
| SCHEMBL1119881 | 0.83 | PTGER3 (0.51) | MAPTUSP30PTGER3PDE3BPDE3A | |
| SCHEMBL7343831 | 0.81 | USP30 (0.48) | ALDH1A1USP30PTGER3CBX7CDYL2 | |
| SCHEMBL3213901 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1USP30PTGER3PDE3BPDE3A | |
| SCHEMBL14565021 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MAPTUSP30PTGER3CBX7 | |
| SCHEMBL474625 | 0.78 | PTGER3 (0.42) | ALDH1A1MAPTUSP30PTGER3CBX7 | |
| SCHEMBL9197069 | 0.77 | PDE3B (0.48) | USP30PDE3BPDE3AKMOTSHR | |
| SCHEMBL14423522 | 0.77 | PTGER3 (0.45) | ALDH1A1MAPTUSP30PTGER3PDE3B | |
| SCHEMBL474378 | 0.77 | CBX7 (0.46) | ALDH1A1MAPTUSP30PTGER3CBX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | ALDH1A1 313/4885MAPT 2057/4885USP30 2692/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | ALDH1A1 736/4885MAPT 1924/4885USP30 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.